Imagion Biosystems December 2021 Investor Newsletter
We are pleased to provide our investors with our December 2021 Investor Newsletter. In this edition, our Executive Director and CEO Bob Proulx gives an…
Employee Spotlight: Carmen Soikowski, Director of Operations
Highlighting our dedicated employees who bring both their experience and passions to Imagion Biosystems: We sat down with Carmen Soikowski, who joined us as…
IBXO Options Exercise Complete
Imagion Biosystems is pleased to advise that it has now received the full $4.8 million from the exercise of all 96,706,395 listed options (IBXO) which had an…
Appendix 2A — Application for Quotation of +Securities
The following Appendix 2A was announced via ASX on 1 Dec 2021. Please click to review full announcement.
Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001
The following cleansing notice was lodged with ASX on December 1, 2021: Imagion Biosystems Limited (ASX: IBX) (the Company) gives notice that, between 26…
Magnetic Nanoparticles as Imaging Agents Presentation at the 2021 VBIC Meeting
As a sponsor of the 2021 Annual VBIC Network Meeting, Imagion Biosystems' President and CEO, Bob Proulx, gave a presentation on magnetic nanoparticles as…
Appendix 2A Application for quotation of +securities
The following Appendix 2A was announced via ASX on 25 Nov 2021. Please click to review full announcement.
Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001
The following cleansing notice was lodged with ASX on November 25, 2021: Imagion Biosystems Limited (ASX: IBX) (the Company) gives notice that, between 19…
IBXO Options Underwriting Agreement — US Based Investor
Imagion Biosystems is pleased to announce it has entered into an options underwriting agreement (Underwriting Agreement) with Mercer Street Global…
Appendix 3Y Change of Director's Interest Notice
The document "Appendix 3Y Change of Director's Interest Notice" was lodged with ASX on 22 November, 2021. Please click to review the full announcement at ASX.